Beta-Casomorphin-7 (BCM-7)
The opioid fragment released from A1 cow's-milk casein during digestion — the molecule at the centre of the A1-vs-A2 milk debate. A food peptide, not a drug, and its disease claims are unproven
Beta-casomorphin-7 (BCM-7) is a seven-amino-acid peptide (Tyr-Pro-Phe-Pro-Gly-Pro-Ile) that is not added to anything — it is released from cow's-milk protein when you digest it. Its parent, beta-casein, comes in two common genetic variants, A1 and A2, differing by a single amino acid at position 67. That one difference matters: the A1 variant is cleaved during digestion to release BCM-7 readily, while the A2 variant (with a proline there) largely resists the cut and releases much less. BCM-7 is an 'exorphin' — a food-derived peptide with opioid activity at the mu-receptor — which is why it has drawn so much attention and marketing around 'A2 milk'. Popular claims tie A1 milk and BCM-7 to autism, type-1 diabetes and heart disease, but these remain unproven: Europe's food-safety authority reviewed the evidence and found no cause-and-effect link, and human studies are weak and inconclusive. Confusingly, in laboratory and animal studies BCM-7 often shows protective effects — against kidney injury, fibrosis and even tumour growth — so its biology is context-dependent, not simply 'good' or 'bad'. BCM-7 is a dietary and research peptide; it is not a medicine.
No established human dose Details ↓
Recommended Dosing
No established human dose
Beta-casomorphin-7 is not taken as a product — it forms in the gut when milk beta-casein is digested. No regulator has approved it as a treatment and no human therapeutic dose exists, so no amount is printed here.
Work out syringe units → · New to syringes? · All dosing data ↓ · Dose and vial tracker · Is this vial OK?
What is it?
Beta-casomorphin-7 is not something you take — it is something your digestion makes. Bovine beta-casein, one of the main proteins in cow's milk, is broken down in the gut into many fragments; one of them, corresponding to residues 60-66, is the opioid heptapeptide Tyr-Pro-Phe-Pro-Gly-Pro-Ile, BCM-7. Because it comes from food and acts on opioid receptors, it belongs to the class of 'exorphins' (exogenous opioid peptides), with activity mainly at the mu-opioid receptor.
What made BCM-7 famous is the A1/A2 milk distinction. Beta-casein exists as genetic variants; the A1 and A2 forms differ at position 67 (histidine in A1, proline in A2). That single change controls how easily digestion cuts out BCM-7: A1 beta-casein releases it readily, while the proline in A2 hinders the cleavage so A2 milk releases much less. Controlled in-vitro digestion studies of milk and cheese confirm this — BCM-7 appears in digests of both but is markedly higher from A1 material, and in one survey of commercial Cheddar, BCM-7 was detected only in cheeses containing the A1 variant. This is the scientific basis for 'A2 milk' products.
The headline health claims, however, outran the evidence. Marketing and some hypotheses have linked A1 milk and BCM-7 to autism, type-1 diabetes, heart disease and digestive discomfort. The European Food Safety Authority reviewed the question in 2009 and concluded there was no cause-and-effect relationship between dietary beta-casomorphins and these non-communicable diseases; subsequent human research on A1 versus A2 milk has been limited, mixed and often focused on short-term digestive comfort rather than disease. A comprehensive 2020 review laid out the structure, release, immunology and claimed health links and explicitly left the pros-and-cons judgement to the reader — a fair reflection of an unsettled field.
Adding to the nuance, laboratory and animal studies often show BCM-7 doing helpful things rather than harmful ones. In rats, BCM-7 reduced sepsis-induced acute kidney injury by dampening NF-kB-driven inflammation and oxidative stress. In kidney cells under high glucose, it blocked the fibrosis-related epithelial-mesenchymal transition by modulating the angiotensin-II/TGF-beta1 pathway — notably through a non-opioid mechanism, since an opioid blocker did not reverse it. In a mouse colorectal-cancer model, BCM-7 enhanced anti-tumour immunity (boosting CD8 T cells) and suppressed tumour growth and metastasis when its breakdown by the enzyme CD10 was blocked — the same CD10 that normally limits how long BCM-7 lasts.
The honest summary is that BCM-7 is a genuine, well-characterised milk-derived opioid peptide whose release differs between A1 and A2 milk, but whose effects on human health are not established and whose popular disease associations are unproven. It is a dietary component and a research peptide, not a medicine, and nothing is sold or dosed here. This page records what the published science says.
Mechanism of Action
Beta-casomorphin-7 is an opioid peptide released from milk beta-casein during digestion, far more from the A1 variant than the A2. It acts partly through the mu-opioid receptor and partly through non-opioid pathways (angiotensin-II/TGF-beta1, NF-kB, immune modulation); the enzyme CD10 (neprilysin) degrades it and limits its duration.
A1-selective release from casein
Digestion of A1 beta-casein (His67) releases BCM-7 readily; the A2 variant (Pro67) resists the cleavage and releases far less (PMIDs 36444023, 42019609).
Opioid and non-opioid actions
Acts as a mu-opioid exorphin, but some effects (anti-fibrotic via AngII/TGF-beta1) are not reversed by naloxone, so they are non-opioid (PMIDs 32799161, 25882007).
Context-dependent biology
In animal/cell models BCM-7 can be protective (kidney injury, fibrosis) and immune-modulating (anti-tumour); CD10 degrades it (PMIDs 30610183, 34360996).
Published Research
These are studies of beta-casomorphin-7 read from their PubMed records on November 7, 2026: a review of its structure, release and claimed health effects; controlled digestion studies documenting greater release from A1 than A2 milk and cheese; and animal and cell studies of its (often protective) biological effects. The work is in vitro and in animals; BCM-7 has not been given to people as a treatment, and the popular A1-milk disease claims are not established (EFSA found no cause-and-effect link).
Beta-casomorphin: a complete health perspective (review)
A comprehensive review of BCM and its derived peptides — their release from milk during gastrointestinal and enzymatic digestion, structure and properties, immunological aspects and claimed links to human health in infants and adults, plus detection methods — written to present the evidence 'in a cyclopedic perspective' and explicitly leave the pros-and-cons judgement to the reader, reflecting an unsettled field.
A1 milk releases more BCM-7 than A2 during simulated digestion
Using in-vitro static gastrointestinal digestion of bovine milk and cheeses, BCM-7 (the Val-Ile... fragment of beta-casein) was released from both A1 and A2 samples but more markedly from the A1 variant; the amount released depended on the digestive enzymes and the protease-to-protein ratio, underscoring that digestion conditions shape any A1-versus-A2 difference (a mechanistic study).
BCM-7 detected only in A1-containing commercial Cheddar
Across 26 commercial US Cheddar cheeses, the beta-casein variant affected which individual beta-casomorphins were released: BCM-7 was detected only in A1/A2 cheeses and not in A2/A2 cheeses, while total beta-casomorphin levels did not differ between the two groups — confirming the A1 variant specifically enables BCM-7 release in a real product (an analytical study).
BCM-7 reduces sepsis-induced acute kidney injury in rats
In a rat cecal-ligation-and-puncture sepsis model, BCM-7 treatment lowered markers of kidney injury (creatinine, BUN, NGAL, Kim-1), reduced TNF-alpha and NF-kB p65 activity while raising IL-10, and improved antioxidant status — attenuating acute kidney injury by curbing inflammation and oxidative stress (a preclinical result, one of several showing protective effects).
BCM-7 blocks high-glucose fibrotic transition in kidney cells (non-opioid)
In kidney tubular (NRK-52E) cells under high glucose, BCM-7 inhibited the fibrosis-associated epithelial-mesenchymal transition — reducing alpha-SMA and vimentin, preserving E-cadherin — by modulating the angiotensin-II/TGF-beta1 pathway; the effect was NOT reversed by the opioid antagonist naloxone, indicating a non-opioid-receptor mechanism (a cell study).
BCM-7 enhances anti-tumour immunity in colorectal-cancer models
In mouse colorectal-carcinogenesis and orthotopic tumour models, BCM-7 shifted lymphocyte populations toward cytotoxic CD8 T cells and, when its degradation by the enzyme CD10 was blocked, suppressed tumour growth and liver metastasis and reduced precancerous lesions — evidence that BCM-7 can enhance anti-tumour immunity, with CD10 controlling how long it acts (a preclinical result).
No Established Human Dose
Beta-casomorphin-7 is not taken as a product — it forms in the gut when milk beta-casein is digested. No regulator has approved it as a treatment and no human therapeutic dose exists, so no amount is printed here. Animal and cell studies use experimental amounts that do not translate to people, and the real-world exposure question is about milk type (A1 versus A2), not a dose.
What this rests on: PMID 36444023, PMID 32799161, PMID 30610183.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no label and no published test that says what forms or vial sizes Beta-Casomorphin-7 (BCM-7) is sold in. A vial's own label is a seller's claim, not a source.
Mixing a vial: a worked example
Unknown: no human dose of Beta-Casomorphin-7 (BCM-7) has been established (see No Established Human Dose below), so there is no amount to work out. The reconstitution calculator does the arithmetic for any vial, water and dose.
Storage before and after mixing
Unknown: no label or published stability study on file says how to store Beta-Casomorphin-7 (BCM-7), before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Beta-Casomorphin-7 (BCM-7) stays intact once mixed.
How it is taken
Unknown: with no established human dose, there is no established way of taking Beta-Casomorphin-7 (BCM-7). What the human studies gave and how is set out under No Established Human Dose.
What to expect, and when
How long it stays in the body: a half-life of short; degraded by the ectoenzyme CD10 (neprilysin), which limits its duration. After about five half-lives almost none is left.
When effects appear: unknown; no source on this page gives a time to effect for Beta-Casomorphin-7 (BCM-7). Results reported in the studies are under Published Research.
Source: half-life: PMID 34360996.
Side effects, and when to stop or get help
From the Side Effects section: No controlled human safety data for BCM-7 itself; dietary exposure is studied via A1-versus-A2 milk; Popular claims linking A1 milk / BCM-7 to autism, type-1 diabetes and heart disease are UNPROVEN — EFSA's 2009 review found no cause-and-effect relationship; Some short-term human studies report less digestive discomfort with A2 than A1 milk, but the evidence is limited and mixed (a milk-comparison signal, not a BCM-7 safety profile); In animal/cell models BCM-7 is often protective (kidney injury, fibrosis, anti-tumour immunity) via opioid and non-opioid pathways — its biology is context-dependent; Material sold online as 'beta-casomorphin-7' is an unregulated research chemical. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Beta-Casomorphin-7 (BCM-7). Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“BCM-7 is a dietary peptide formed during digestion, not a drug given to people, so there is no clinical adverse-event profile; the points below reflect that and the state of the evidence”).
Interactions
Unknown: a PubMed search for human interaction studies of Beta-Casomorphin-7 (BCM-7) (reviewed 2026-11-07) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Beta-Casomorphin-7 (BCM-7) products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: Research Chemical (Not a drug: Drugs@FDA and the openFDA label endpoint hold no record, and FDA GSRS and ChEMBL hold no drug record for beta-casomorphin-7 (searched November 7, 2026)). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
BCM-7 is a dietary peptide formed during digestion, not a drug given to people, so there is no clinical adverse-event profile; the points below reflect that and the state of the evidence.
Contraindications & Cautions
BCM-7 is a food-derived peptide, not an approved medicine. These points reflect that status.
Legal Status
Beta-casomorphin-7 is a food-derived opioid peptide formed during milk digestion; it is not a drug and is not approved in any country.
Frequently Asked Questions
?What is beta-casomorphin-7?
An opioid peptide (Tyr-Pro-Phe-Pro-Gly-Pro-Ile) released from cow's-milk beta-casein during digestion. It is a food-derived 'exorphin' with mu-opioid activity, not a drug you take.
?What is the A1-versus-A2 milk thing?
The A1 beta-casein variant releases BCM-7 readily during digestion; the A2 variant (proline at position 67) resists the cut and releases far less. That difference is the basis of 'A2 milk' products (PMIDs 36444023, 42019609).
?Does A1 milk / BCM-7 cause autism, diabetes or heart disease?
The evidence does not show that. The European Food Safety Authority's 2009 review found no cause-and-effect relationship, and human studies are limited and mixed. These claims are unproven.
?Is it good or bad for you?
Unsettled. Laboratory and animal studies often show BCM-7 being protective (kidney injury, fibrosis, anti-tumour immunity), while some people report better digestive comfort with A2 milk. Its human health effects are not established. Grey Peptides lists no sellers and recommends nothing.
References
- [review] Thiruvengadam M, et al. "β-Casomorphin: A complete health perspective." Food Chem, 2021;337:127765. PMID: 32799161.
- [mechanism] Cattaneo S, et al. "Impact of in vitro static digestion method on the release of β-casomorphin-7 from bovine milk and cheeses with A1 or A2 β-casein phenotypes." Food Chem, 2023;404(Pt A):134617. PMID: 36444023.
- [mechanism] Daniloski D, et al. "Comparison of the proteolysis and occurrence of a range of β-casomorphin peptides in commercial United States Cheddar cheeses manufactured from A1/A2 and A2/A2 β-casein milks." J Dairy Sci, 2026;109(8):7832-7843. PMID: 42019609.
- [animal] Zhang Z, et al. "β-Casomorphin-7 Ameliorates Sepsis-Induced Acute Kidney Injury by Targeting NF-κB Pathway." Med Sci Monit, 2019;25:121-127. PMID: 30610183.
- [mechanism] Zhang W, et al. "Beta-casomorphin-7 prevents epithelial-mesenchymal transdifferentiation of NRK-52E cells at high glucose level: Involvement of AngII-TGF-β1 pathway." Peptides, 2015;70:37-44. PMID: 25882007.
- [animal] Mori S, et al. "Enhancement of Anti-Tumoral Immunity by β-Casomorphin-7 Inhibits Cancer Development and Metastasis of Colorectal Cancer." Int J Mol Sci, 2021;22(15). PMID: 34360996.
- [other] Beta-casomorphin-7 is the peptide Tyr-Pro-Phe-Pro-Gly-Pro-Ile corresponding to residues 60-66 of bovine beta-casein; it is released from the milk protein by gastrointestinal and enzymatic digestion, more readily from the A1 beta-casein variant than the A2 variant, as described in the review and digestion studies carded on this page (read November 7, 2026).
- [other] US FDA, Drugs@FDA and the openFDA label endpoint, searched November 7, 2026: no application and no label record for beta-casomorphin-7. It is a food-derived peptide formed during digestion of milk, not a drug; FDA GSRS and ChEMBL hold no drug record for it. The European Food Safety Authority (EFSA) reviewed beta-casomorphins in 2009 and found no cause-and-effect relationship between their dietary intake and the proposed non-communicable diseases.
Sources & Citations
The six studies carded above were read from their PubMed records on November 7, 2026. BCM-7's structure (Tyr-Pro-Phe-Pro-Gly-Pro-Ile, beta-casein 60-66), its greater release from A1 than A2 milk and cheese, its opioid and non-opioid actions, and its context-dependent (often protective) effects in animal and cell models are from the review and studies carded here; the absence of US drug approval was checked the same day via Drugs@FDA, openFDA, FDA GSRS and ChEMBL, and the EFSA 2009 conclusion of no proven disease link is cited as the authoritative dietary review. Grey Peptides sells nothing and links to no vendor.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.